Abstract: As a new type of therapeutic drug, immune checkpoint inhibitors (ICIs) has greatly enriched the cancer therapies. However, the subsequent emergence of immune-related response patterns, such as pseudoprogression, delayed response and hyperprogression have challenged the current response evaluation criteria in malignant tumors. Therefore, researchers have constantly revised the relevant evaluation criteria to enable them to assess the therapeutic effects more objectively and guide the formulation of clinical therapy more scientifically. This paper reviews the immunotherapy-related response evaluation criteria in malignant tumors proposed in recent years.